Online inquiry

IVTScrip™ mRNA-Anti-TNFRSF17, C11D5.3 scFv-8A-F9Z CAR(Cap 1, Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ4914MR)

This product GTTS-WQ4914MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & Pseudo-UTP. It ecodes the monoclonal antibody that targets TNFRSF17 gene. The antibody can be applied in Multiple myeloma (MM) research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 1
Species Chimeric
RefSeq NM_001192.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 608
UniProt ID Q02223
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-TNFRSF17, C11D5.3 scFv-8A-F9Z CAR(Cap 1, Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ4914MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ6709MR IVTScrip™ mRNA-Anti-EGFR, DS 1024(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA DS 1024
GTTS-WQ12935MR IVTScrip™ mRNA-Anti-MUC1, PankoMab(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA PankoMab
GTTS-WQ10347MR IVTScrip™ mRNA-Anti-IL17A&TNFSF13B, LY 3090106(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA LY 3090106
GTTS-WQ10872MR IVTScrip™ mRNA-Anti-B4GALNT1, MAb-14.18(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA MAb-14.18
GTTS-WQ3732MR IVTScrip™ mRNA-Anti-TFPI, BAY-1093884(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA BAY-1093884
GTTS-WQ12170MR IVTScrip™ mRNA-Anti-MSLN, MORAb-009(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA MORAb-009
GTTS-WQ13524MR IVTScrip™ mRNA-Anti-MCAM, PRX-003(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA PRX-003
GTTS-WQ15562MR IVTScrip™ mRNA-Anti-NGcGM3, UNII-52G405U1E5(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA UNII-52G405U1E5
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW